When You Are in a Hurry and Looking for Just the Right Expert Witness to Win Your Case.
800-683-9847

Endocrinology Thyroid Cancer Hormonal Expert Witness

Speak with this Expert

for Free

We respond in as little as 1 hour

Request This Expert

    • Speak with Representative
    • Receive CV / Fees
    • Speak with Expert

    For Immediate Service or Questions
    Call 800-683-9847

    We respond in as little as 1 hour M-F 8-5pm PT or the next business day for requests submitted outside business hours.

Why CCC?

N
Expansive Network of Over 30,000 Experts

100’s of categories of highly-qualified medical and technical experts in just about every state, for just about any type of case.

We’re Trusted in Over 10,000 Legal Cases

Since 1995 we’ve worked with 1,000’s of medical malpractice, personal injury and government cases in every state and region.

We’re Fast – Search for Free

We respond in less than 1 hour. We’ll search for you or search CV’s on our site by keyword, category, state or region – both are free!

         

Quickly Find The Right Expert In 3 Easy Steps
  1. You request an expert or search our site for free.
  2. We schedule a free conference call with the expert.
  3. You decide the right expert for your case.

We respond in as little as 1 hour

 

Free Expert Witness Search and Recruiting

You’ll pay nothing to have us do the hunting for the perfect expert witness for you. If, for any reason we don’t have the perfect expert in our network, as always, we’ll do the recruiting for free. Since 1995, we continue to expand our network.

       


Endocrinology Thyroid Cancer Hormonal Expert Witness

Provides Opinion & Testimony In:

Endocrinology, Diabetes, Hypoglycemia, Thyroid Disease, Cancer, Hormonal Treatments, Testosterone Therapy, Osteoporosis, Adrenal Glands, Neuro-Endocrinology, DUI with Diabetes, Workplace Accommodations, Pharmaceutical Drug, Devise Safety, Medical Big Data, Pharmaco-economics, Obesity, Lipid Treatments, Cardiovascular Treatments

EXPERT 5060

Education

  • 1970 B.A., University of Virginia (Magna Cum Laude)
  • 1974 M.D., University of Maryland

Post Graduate Education and Training

  • 1974-1977 Internship/Residency, Yale-New Haven Hospital & Affiliates, School of Medicine, Medicine PG I, PG II, Pathology
  • 1977-1978 Residency, Georgetown University Hospital, Medicine PG III
  • 1978-1980 Fellowship, Endocrine,The Ohio State University Hospital
  • 1980- 1982 NIH Clinical Associate, National Institute of Aging- Metabolism

Certifications

  • 1975 Board Certified- Internal Medicine, Maryland
  • 1978 Board Certified- Internal Medicine, Ohio
  • 1978 Diplomat, American Board of Internal Medicine
  • 1981 Board Certified- Endocrinology and Metabolism- A.B.I.M.

Medical Licensures

  • 1975 Active Maryland
  • 1978 Inacticve Ohio

Employment History

Academic
Appointments

  • 1980- 1982 Instructor in Medicine, Johns Hopkins University, School of Medicine
  • 1982- 1989 Assistant Professor, University of Maryland, School of Medicine
  • 1989- 1994 Associate Professor, University of Maryland, School of Medicine
  • 2000- 2008 Associate Clinical Professor, Division of Endocrinology, University of Maryland, School of Medicine
  • 2011- present Assistant Professor of Medicine, Johns Hopkins University School of Medicine
  • 8/2017- present Adjunct Associate Professor, University of Maryland, School of Medicine

Professional Society Membership

  • 1994- 1996 General Member, American Medical Association
  • 1994- 2000 General Member, The Endocrine Society
  • 1994- present Professional Section Member, Complications Committee, American Diabetes Association
  • 2008- present General Member, Americian Association of Clinical Endocrinologists
  • 2009- 2010 General Member, American Federation for Clinical Research
  • 2010- 2017 Executive Committee, Johns Hopkins Clinical Research Network, Johns Hopkins Medical Institution

Clinical Activities

Clinical
Expertise

  • Board Certified Endocrinologist
  • Additional board certification in the sub specialty of endocrinology and metabolism Research focus in the area of endocrinology and metabolism

Institutional Service

  • 2014- present Chairman, Greater Baltimore Medical Center Institutional Review Board

Local and National Service

  • 2009- present Consultant, Endocrine and Diabetes

Teaching Service

1982- 1985 Consultant Attending
Division of Endocrinology- Department of Medicine
University of Maryland School of Medicine
2000- 2008 Medical House Staff Attending Rounds

Teaching Conferences
Mercy Hospital
2009- present Medical House Staff Noon

Teaching
Greater Baltimore Medical Conference Center

Grant Support

  • Active Grants
  • 2004- present TrialNet Natural History Study of the Development of Type 1 Diabetes,
    NIH
  • 2012- present A large-scale, randomized placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease (Randomized EValuation of the Effects of Anacetrapib through Lipid-modification) , CTSUREVEAL1 ; HPS 3/ TIMI 55: REVEAL
    Merck
  • 2014- present Co- Investigator: A Case – Finding Approach to Screening for Monogenic Diabetes, National Human Genome Research Institute (NHGRI),
    NIH, Principal Investigator: Toni Pollin, MS, PhD
  • 2014- present A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment with BELVIQ (lorcaserin HCI) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects with Cardiovascular Disease or Multiple Cardiovascular Risk Factors APD356-G000-401
    Eisai
  • 2015- present PARADIGHM (Physicians Advancing Disease Knowledge in Hypoparathyroidism): A Natural History Registry for Patients with Chronic Hypoparathyroidism, PAR-R13-001
    NPS Pharmaceuticals, Inc.
  • 2016- present Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk Open Label Extension, Fourier OLE Study
    Amgen
  • 2016- present Efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes and moderate renal impairment, NN9924-4234 (PIONEER)
    Novo Nordisk
  • 2016- present Getting to an imprOved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia management (GOULD): a Registry of High Cardiovascular Risk Subjects in the United States
    Amgen
  • 2017- present A randomized, double-blind, placebo-controlled, event
    driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with elevated hsCRP, Open Label Extension CACZ885M2301 Novartis
  • 2017- present Efficacy and Safety of Semaglutide once weekly versus placebo as add-on to SGLT-2i in subjects with type 2 diabetes mellitus, NN9535-4269
    Novo Nordisk
  • 2017- present A digital health tool for insulin titration (DHIT) for individuals with type 2 diabetes: a prospective outcomes study with a retrospective control group isage Rx, Inc.
  • 2017- present A randomized, double-blind, dose finding study to evaluate the change in weight after 24 weeks treatment with 8 doses of LIK066 compared to placebo in obese or overweight adults, followed by 24 weeks treatment with 2 doses of LIK066 and placebo, CLIK066
    Novartis
  • 2018- present Initiating Mealtime Ultra-Rapid Acting Insulin (Afrezza) in Uncontrolled Type 2 Diabetes Patients, Mannkind
  • 2018- present A Randomized, Multi-center, Double-Blind, Parallel-Group Clinical Study Comparing the Efficacy and Safety of MYL-1501D Produced by 2 Manufacturing Processes in Type 1 Diabetes Mellitus Patients, Mylan

Completed Grants

  • 1983-1985
    • Glipizide Sulfonylurea, Phase II Trial
      Pfizer Pharmaceuticals
  • 1986- 1993
    • Diabetes Control and Complications Trial NIH
  • 1997- 2002
    • Osteoporosis Studies on Ibandronate
      Roche Pharmaceuticals
  • 1997- 2003
    • Evista Studies
      Eli Lilly Pharmaceuticals
  • 1999
    • Diabetes Control and Lipids Study Parke-Davis
  • 2000- 2005
    • Insulin Lispro Low Mixture Plus Metformin Compared to NPH Insulin Plus Metformin in Subjects with Type 2 Diabetes
      Eli Lilly
    • Rosiglitazone Monotherapy compared to Metformin or Glyburide in Type 2 Diabetics
      Glaxo SmithKline
    • Pioglitizone vs. Rosiglitazone in Type 2 Diabetics Eli Lilly
    • Omapatrilat Cardiovascular Treatment Assessment vs. Enalipril Bristol-Myers Squibb
    • Synthetic 10-Component Conjugated Estrogen vs. Placebo for Prevention of Osteoporosis in Hysterectomized, Postmenopausal Women
      Endeavor Pharmaceuticals
    • Oral Insulin Spray studies Generex Pharmaceuticals
    • Sub Investigator: Comparing effects of Carvedilil and Metoprolol on Glycemic Control in Hypertensive and Type II Diabetes Mellitus Patients, Principal Investigator: James H. Mersey, MD
      SmithKline Beecham
    • Comparing Celecoxib, Rofecoxib and Naproxen in Hypertensive Patients with Osteoarthritis and Type II Diabetes Mellitus
      Pharmacia
    • Placebo Controlled Dose Finding Study of KAD-1229 in Type II Diabetic Patients
      Kissei Pharmaceuticals
    • Sub Investigator: Open Label Trial to Assess Noninferiority Between Pre and Post-meal Administration of CMR 1964 and Pre-meal Regular Human Insulin in Type I Diabetes Mellitus Patients Receiving Insulin Glargine as the Basal Insulin therapy, Principal Investigator: James H. Mersey, MD
      Aventis Pharmaceuticals,
    • Sub Investigator: The Impact of Medical Subspecialty on Patients Compliance to Treatment, Principal Investigator: James H. Mersey, MD Kos/Dupont Pharmaceuticals
    • Sub Investigator: Comparing HMR 1964 with Regular Human Insulin Injected Subcutaneously in Subjects with Type 2 Diabetes Mellitus Also Using NPH Insulin, and Which Will Lead into a Comparative 26 Week Safety Extension Study, Principal Investigator: James H. Mersey, MD
      Aventis Pharmaceuticals
    • Sub Investigator A Randomized, Double- Blind, Dose Ranging, Dose Comparison- Controlled Trial to Determine the Safety and Efficacy of BMS- 298585 in Subjects with Type 2 Diabetes, Principal Investigator: James H. Mersey, MD
      Bristol-Myers Squibb
    • Sub Investigator: The Safety and Efficacy of Omapatrilat Modified Release Formulation in Subjects with Mild to Moderate Hypertension, Principal Investigator: James H. Mersey, MD
      Bristol-Myers Squibb
    • Sub Investigator: Evaluation of Diabetic Retinopathy Progression in Subjects with Type 2 Diabetes Mellitus Treated with Insulin,
      Principal Investigator: James H. Mersey, MD Aventis Pharmaceuticals
    • Sub Investigator: Simvastatin and Fenofibrate Efficacy Trial, Principal Investigator: James H. Mersey, MD
      Merck and Co
    • Sub Investigator: A Randomized Trial of an Angiotensin II Receptor Antagonist (Telmisartan) and an ACE-Inhibitor (Ramipril) in Patients at High Risk for Cardiovascular Events and a parallel study, Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease, Principal Investigator: James H. Mersey, MD
      Boehringer Ingelheim
    • Evaluating the Efficacy and Safety of Tolterodine versus Placebo in the Treatment of Urinary Urgency and Frequency
      Pharmacia
    • Comparing 3 Doses of Conjugated Estrogens with Placebo in Hysterectomized Postmenopausal Women for the Prevention Of Osteoporosis
      Endeavor Pharmaceuticals
    • Comparing a Stratified Care Treatment Regimen versus Standard Therapy for the Acute Treatment of Migraine Headaches
      Astra Zeneca
    • Sub Investigator: Comparing the Effects of Lotrel to Amlodipine and Benazepril on Systolic Blood Pressure and Pulse Pressure in Patients with Systolic Hypertension, Principal Investigator: James H. Mersey, MD Novartis Pharmaceuticals
    • Sub Investigator: Correction of Hemoglobin and Outcomes in Renal Insufficiency, Principal Investigator: James H. Mersey, MD
      Ortho Biotech
    • Improvement of Brittle Diabetes Control After Switching to Insulin Glargine from NPH Insulin: A Continuous Glucose Monitoring System
      Aventis
    • The Effect of LY333531 on Albuminuria in Patients with Type 2 Diabetes Eli Lilly and Company
    • Treatment of Peripheral Neuropathy in Patients with Diabetes: A Phase 3 Pivotal Clinical Trial
      Eli Lilly and Company
    • Treatment for Symptomatic Peripheral Neuropathy in Patients with Diabetes
      Eli Lilly and Company
    • A Double-blind, Multi-center, Randomized, Placebo-controlled, Parallel Group Dosing Study of the Effects of Nebivolol on Blood Pressure in Black Patients with Mild to Moderate Hypertension
      Bertek
    • A Multi-center, Parallel Group Extension Study to Determine the Safety and Efficacy of Long-Term Nebivolol Exposure in Patients with Mild to Moderate Hypertension
      Bertek
    • A Double-blind, Multi-center, Randomized, Placebo Controlled, Parallel Group Study of the Efficacy and Safety of Nebivolol Added to Existing Antihypertensive Treatment in Patients with Mild to Moderate Hypertension Bertek
    • A Multi-center, Randomized, Double-blind, Double-dummy Study Evaluating the Safety and Efficacy of the Addition of Amlodipine to Quinapril or Losartan in the Treatment of Diabetic Hypertensive Subjects
      Pfizer
    • A One Year, Open, Randomized, Parallel, Three-Arm Study Comparing Exubera vs. Avandia as Add on Therapy vs, Exubera Substitution of Sulfonylurea in Patients with Type 2 Diabetes, Poorly Controlled on Combination Sulfonylurea and Metformin Treatment
      Pfizer
    • A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Dose-Range Finding Study of Once Daily Dosing of L-000224715 in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control
      Merck
    • Assessment of Biomarkers in Diabetes Hoffmann-La Roche
    • A Phase 3B, Multi-Center, Open Label Study Investigating the Clinical Utility and Safety of Pramintide in Subjects with Type 1 and Type 2 DiabetesMellitus Who Have Not Achieved Glycemic Targets with Insulin Therapy
      Amylin
    • The Global Hypopituitary Control and Complications Study (HypoCCS) Lilly
    • APIDRA Administered in a Fixed Bolus Regimen vs. a Variable Bolus Regimen Based on Carbohydrate Counting in Adult Subjects with Type 2 Diabetes Receiving Lantus as Basal Insulin: A Multicenter, Randomized, Parallel Open Label Clinical Study
      Aventis
    • Effects of Arzoxifene on Vertebral Fracture Incidence and on Invasive Breast Cancer Incidence in Postmenopausal Women with Osteoporosis or with Low Bone Density
      Lilly
    • Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group Evaluation of the Fixed Combination Torcetrapib/Atorvastatin, Administered Orally, Once Daily Compared with Atorvastatin Alone, on the Occurrence of Major Cardiovascular Events in Subjects with Coronary Heart Disease or Risk Equivalents
      Pfizer
    • 3S Confidence Glucose Monitoring System Alternate Site (Forearm) Capillary Evaluation
      Roche

      TrialNet Natural History Study of the Development of Type 1 Diabetes, NIH Baltimore-Washington Major Affiliate
      NIH

  • 2006
    • Type 1 Diabetes Genetics Consortium NIH, NIDDK, JDRF
    • A Prospective Randomized Trial Of The Cost Effectiveness Of Lantus Plus Apidra Compared To Premix Analog Insulin Regimens In Patients With Type 2 Diabetes (Lace)
      sanofi aventis
    • Pulmonary Outcomes within a 2 Year Period in Subjects with Diabetes Mellitus Treated with Technosphere Insulin or Usual Antidiabetic Treatment, Mannkind
    • A Double-Blind, Multi-Center, International (US and Europe), Randomized, Placebo-Controlled Study of Safety and Efficacy of Trospium Chloride 60 Mg Modified Release Capsules Versus Placebo, Once Daily, For 12 Weeks Followed By a 9-Month, Open-Label Treatment Phase In Patients With Overactive Bladder
      Indevus
    • The Durability of Twice-Daily Insulin Lispro Low Mixture Compared to Once- Daily Insulin Glargine when added to Existing Oral Therapy in Patients with Type 2 Diabetes and Inadequate Glycemic Control
      Lilly
    • Effects of NovoLogC› Mix 70/30 (biphasic insulin aspart 70/30) BID and QD vs. Byetta TM (exenatide) BID on Glycemic Control: A Multicenter, 24-Week,
      Open-Label, Parallel Group Study in Patients with Type 2 Diabetes Mellitus not Achieving Glycemic Targets with Metformin and a Sulfonylurea
      Novo Nordisk
    • A Phase 2a, Randomized, Double-blind, Placebo-controlled, Multi-Center Study to Examine Safety and Establish Proof of Concept with PHX1149 in Patients with Type 2 Diabetes Mellitus
      Phenomix
    • A Phase 3, Open-Label, Parallel-Group Study to Evaluate the Efficacy of Preprandial Human Insulin Inhalation Powder (HIIP) Compared to Preprandial Injectable Insulin in Patients with Type 1 Diabetes Mellitus
      Lilly
    • GOLD (ACCU-CHEKO Performa) Glucose Monitoring System Alternate Site Capillary Evaluation
      Roche
    • A Phase 3, Open-Label, Three-Group Parallel Study to Evaluate the Efficacy and Safety of Human Insulin Inhalation Powder (HIIP) in Patients with Type 2 Diabetes Treated with Once-Daily Insulin Glargine
      Lilly
    • Lipid Treatment Assessment Project Pfizer
    • A 2-Year, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study To Evaluate The Long-Term Efficacy And Safety Of CP-945,598 In The Treatment Of Obese Subjects
      Pfizer
    • A 1-Year, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study To Evaluate The Efficacy And Safety Of CP-945,598 In The Treatment Of Overweight, Oral Agent-Treated Subjects With Type 2 Diabetes Mellitus, Pfizer
  • 2007
    • A study to compare Exubera inhaled insulin with injectable insulin Pfizer
    • A Prospective, Randomized, Naturalistic Study Using Insulin Glargine or Detemir to Treat Patients With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Medications Alone
      sanofi aventis
    • An Open Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAJECT and Regular Human Insulin in Patients with Type 1 Diabetes Mellitus
      Biodel
    • Correlation Between the TCF7L2 Test and Diabetes Drug Response in Type 2 Diabetics
      deCode Genetics
  • 2008
    • A Double-Blind, Randomized, Placebo-Controlled, 5-Arm Titration Study to Evaluate the Efficacy and Safety of TAK-491 When Compared With Valsartan and Olmesartan in Subjects With Essential Hypertension
      Takeda
    • A multi-centre, randomised, open-label, cross-over study to explore effectiveness, safety and preference of a new disposable pen PDS290 vs. FlexPeno in subjects with type 1 or type 2 diabetes
      Novo Nordisk
    • Freedom 9 mm (ACCU-CHEK% Aviva) Glucose Monitoring System Alternative Site Capillary Evaluation
      Roche

      Freedom 7mm (ACCU-CHEKO Performa) Glucose Monitoring System Patient vs Techncian Capillary Evaluation
      Roche

    • A Multicenter, Randomized, Placebo-Controlled, “Factorial” Design, 12-Month Study To Evaluate The Efficacy And Safety Of AVE5530 25 Mg/Day And 50 Mg/Day Co-Administered With All Registered Atorvastatin Strengths Ranging From 10 Mg To 80 Mg In Patients With Primary Hypercholesterolemia
      sanofi aventis
    • A 12-Week, Double-Blind, Placebo-Controlled Trial of LY2428757 in Patients with Type 2 Diabetes Mellitus
      Eli Lilly
    • The Effect Of Insulin Detemir In Combination With Liraglutide And Metformin Compared To Liraglutide And Metformin In Subjects With Type 2 Diabetes. A 26-Week, Randomised, Open-Label, Parallel-Group, Multicentre, Multinational Trial With A 26-Week Extension
      Novo Nordisk
    • A Retrospective Clinical Practice Evaluation Of Lantus Cost Effectiveness Compared To Levemir In Diabetes Patients ( Lace 2 Pilot Study ) sanofi aventis
  • 2009
    • LACE EMR Multi-Site Study – A Retrospective Clinical Practice Evaluation Of Lantus Cost-Effectiveness Compared To Levemir In Insulin-Naive Type 2 Diabetes Patients (Insulin Naive EMR Study)
      sanofi aventis
      A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Dutogliptin in Patients with Type 2 Diabetes Mellitus on Background Treatment with Glimepiride with or without Metformin
      Forest Research
    • A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Dutogliptin in Patients with Type 2 Diabetes Mellitus on Background Treatment with Pioglitazone
      Forest Research
    • Glycemic Effects Of Nebivolol Compared With Metoprolol Extended Release And Compared With Hydrochlorothiazide In Hypertensive Patients With Type 2 Diabetes Mellitus: A Pilot Study, NEB-MD-19
      Forest Research
    • A Trial Comparing Efficacy And Safety Of NN5401 With Insulin Glargine, Both In Combination With Oral Antidiabetic Drugs In Subjects With Type 2 Diabetes – NN5401-3593
      Novo Nordisk
    • Accu-Chek Aviva Glucose Monitoring System Alternative Site Capillary Evaluation Patient vs. Technician, D8026-09-32
      Roche
    • A Phase 2 Study of LY2605541 Compared with Insulin Glargine in the Treatment of Type 2 Diabetes Mellitus – I2R-MC-BIAC
      Eli Lilly
    • A Phase 2 Study of LY2605541 Compared with Insulin Glargine in the Treatment of Type 1 Diabetes Mellitus – 12R-MC-BIAD
      Eli Lilly
    • A 26-Week, Randomised, Controlled, Open Label, Multicentre, Multinational, Three-Arm, Parallel, Treat-To-Target Trial Comparing Efficacy And Safety Of Two Different Dosing Regimens Of SIBA And One Dosing Regimen Of InsulinGlargine, Both In Combination With Meal-Time Insulin Aspart In Subjects With Type 1 Diabetes Mellitus – NN1250-3770
      Novo Nordisk
  • 2010
    • A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study To Evaluate Cardiovascular Outcomes During Treatment With Lixisenatide In Type 2 Diabetic Patients After An Acute Coronary Syndrome – EFC11319
      sanofi aventis
    • Sub Investigator: Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study To Evaluate The Effect Of 5 Mg Or 20 Mg Nebivolol Once Daily On Blood Pressure N Patients With Systolic Stage 2 Hypertension, NEB-MD- 20, Principal Investigator: James H. Mersey, MD
      Forest Research
    • A Randomized, Double-Blind, Parallel-Group Study To Evaluate The Effects Of First Line Treatment With A Free Combination Of Nebivolol And Lisinopril Compared With Placebo And The Monotherapy Components On Blood Pressure In Patients With Stage 2 Diastolic Hypertension, NEB-MD-25 Forest Research
    • Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results A Long-term, Multi-centre, International, Randomised Double-blind, Placebo-controlled Trial to Determine Liraglutide Effects on Cardiovascular Events
      Novo Nordisk
    • Protocol #: D8026-10-17 Freedom II 7 mm (ACCU-CHEKC› Performa) Test Strip with the ACCU-CHEKO Performa Glucose Monitoring System (Alternative Site Capillary Evaluation)
      Roche Diagnostics
    • 2011 An open label randomized multicenter study to assess patient preference for and evaluate clinical benefit of insulin glargine (Lantuso) SoIoSTARO pen versus conventional vial/syringe method of insulin glargine (Lantuso) injection therapy in patients with type 2 diabetes mellitus, Lantu L 05191
      sanofi aventis
  • 2012
    • Effectiveness of V-Go TM for Patients with Diabetes in a Real-world Setting: A Long-term, Prospective, Observational Registry (SIMPLE) Study, V4006 Valeritas
    • A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Safety and Insulin-Sparing Efficacy of the Addition of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Insulin Alone or in Combination With Metformin, MK- 0431, Protocol 260
      Merck
    • A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When AMG 145 is Used in Combination With Statin Therapy In Patients with Clinically Evident Cardiovascular Disease, AMG 145 20110118
      Amgen
    • Glycemia in Diabetic Elders (GLiDE) Trial Johns Hopkins Clinical Research Network
  • 2013
    • Protocol D01792.01-12-07 ACCU-CHEN Aviva (No Code) Glucose Monitoring System with the ACCU-CHEK” Aviva Plus Test Strip ISO 15197 Section 8 User Performance Evaluation
      Roche
    • Protocol D01792.01-12-08 ACCU-CHEK” Aviva (No Code) Glucose Monitoring System with the ACCU-CHEK” Aviva Plus Test Strip Alternative Site Capillary Evaluation
      Roche
    • Sub Investigator: A Phase III Clinical Trial to Study the Safety and Efficacy of K-1293 Compared to Lantus TM in Subjects with Type 1 Diabetes Mellitus
      Principal Investigator: James H. Mersey, MD Merck, Sharp and Dohme Corporation
    • Efficacy and Safety of FIAsp compared to insulin aspart both in Combination with insulin detemir in Adults with Type 1 Diabetes Onset” 1
      Novo Nordisk
  • 2014
    • A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events (MACE) in Overweight and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR/Bupropion SR (LIGHT Study)
      Parexel Orexigen
    • A randomized, double-blind, placebo-controlled, event driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with elevated hsCRP, CACZ885M2301
      Novartis
    • A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment with BELVIQ (lorcaserin HCI) of the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects with Cardiovascular Disease or Multiple Cardiovascular Risk Factors APD356- G000-401, Eisai
    • NIH: A Case – Finding Approach to Screening for Monogenic Diabetes, National Human Genome Research Institute (NHGRI), Co- Investigator
  • 2015
    • LX4211-309: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of LX4211 as Adjunct Therapy in Adult Patients with Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control with Insulin Therapy, Lexicon
    • BI1245.72: A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to insulin thErapy over 26 weeks in patients with Type 1 Diabetes Mellitus (EASE-3), Boehringer Ingelheim
    • NN1218-4131: Efficacy and Safety of Faster-acting Insulin Aspart compared to NovoRapido both in combination with Insulin Degludec in Adults with Type 1 Diabetes, Novo Nordisk
Groups